RMG-G9

RMG-G9 is a preclinical-stage drug candidate developed by RxOmeg Therapeutics, a pharmaceutical company focused on reformulating well-characterized small molecules to address unmet needs in rheumatologic and cardiac inflammatory diseases. RMG-G9 is specifically being developed for the treatment of viral and inflammatory syndromes. As a reformulated version of an existing small molecule, the drug aims to provide improved therapeutic outcomes or novel delivery methods for established active ingredients. While the specific identity of the underlying molecule and its precise mechanism of action have not been publicly disclosed, the program aligns with RxOmeg's strategy of targeting high unmet needs and orphan indications through innovative formulations.